NCT07682285Completed
Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors
Effects of Taiwanese Green Propolis (2,000 mg/Day) on Lipid Profiles, Cancer-Related Fatigue, and Quality of Life in Post-Treatment Oral Cavity Squamous Cell Carcinoma Survivors: A Double-Blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This study examined whether Taiwanese Green Propolis (TGP), a natural bee-derived supplement, can improve blood fat levels, reduce tiredness (fatigue), and improve quality of life in people who have completed treatment for oral cavity (mouth) cancer. People who had finished treatment for oral cavity squamous cell carcinoma (a type of mouth cancer) and were in the follow-up period were invited to participate. Participants were randomly assigned to take either 4 TGP capsules per day (2,000 mg/day total) or 4 identical-looking placebo capsules for 12 weeks. Neither participants nor the study team knew who received which capsules until after the study ended (double-blind). All participants were followed for a further 12 weeks after stopping the capsules. At the start and at Weeks 4, 8, 12, and 24, participants had blood tests to measure cholesterol, triglycerides, liver enzymes, and inflammation markers. They also completed questionnaires about fatigue (BFI-T), symptoms (ESAS-r), and quality of life (FACT-H\&N), and performed physical tests including grip strength and a 30-second sit-to-stand test. The study aimed to determine whether TGP can help manage the metabolic and fatigue-related problems common after oral cancer treatment, and to provide data for planning larger future trials. 25 participants were enrolled at a regional teaching hospital in northern Taiwan. Stool and saliva samples were also collected at each timepoint to assess gut and oral microbiota composition (16S rRNA sequencing) and salivary inflammatory markers. Heart rate variability was monitored via smart wristband (minimum 24 hours per timepoint).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 26 Jun 2026
- Start date
- 22 May 2024
- Primary completion date
- 26 Jun 2026
- Lead sponsor
- Taipei Medical University
- Diseases
- Head and neck cancer
- NCT number
- NCT07682285
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 22 May 2024 to the primary completion date, 26 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to propolis, honey, multiple pollens, or alcohol
- Psychiatric disorder or cognitive impairment preventing study participation
- Neuromuscular or joint disorders preventing performance of grip strength or sit-to-stand assessments
Other
- Pain at testing limb sites preventing physical assessments
Who the study is looking for
- Age 18 years or older
- Histologically confirmed diagnosis of oral cavity squamous cell carcinoma (OSCC)
- Post-primary treatment follow-up phase (surgery with or without adjuvant radiotherapy and/or chemotherapy completed)
- Alert and oriented; able to complete study assessments independently or with research staff assistance
- Able to communicate in Mandarin or Taiwanese
- Not chewing betel quid during the study period
- Willing to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taipei Medical University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.